BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
May 08, 2006
 |  BioCentury  |  Finance

EPS watch

EPS watch

EPS watch
PDL (PDLI) and ViroPharma (VPHM) both had big declines after reporting first quarter numbers that were worse than expected. On the upside, Myriad (MYGN) jumped 11% after posting strong sales growth for its predictive medicine products. (A) Results for 2Q ended March 31; (B) Results for 3Q ended March 31; Mcap in $M
Company 1Q06 EPS est 1Q06 EPS actual Outcome Growth from 1Q05 5/5 cls Wk chg % chg Mcap chg 5/5 Mcap
Axcan (TSX:AXP; AXCA) (A) $0.16 $0.17 Beat by $0.01 42% $13.94 $0.52 4% $23.8 $637.1
The gastrointestinal company reported 2Q06 revenues of $72.8M, up 15% vs. $63.4M in 2Q05. Citing stronger than expected North American sales for the quarter, the company raised its FY06 revenue guidance to $270-$280M from $260-$270M, which would be up 8-12%...

Read the full 771 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >